Nevro Corp (NYSE:NVRO) Director Elizabeth H. Weatherman purchased 2,460 shares of the company’s stock in a transaction on Friday, June 7th. The shares were bought at an average price of $60.99 per share, for a total transaction of $150,035.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Nevro stock opened at $62.01 on Tuesday. The company has a market capitalization of $1.85 billion, a PE ratio of -37.81 and a beta of 0.25. The company has a current ratio of 6.30, a quick ratio of 4.87 and a debt-to-equity ratio of 0.83. Nevro Corp has a fifty-two week low of $34.75 and a fifty-two week high of $86.75.
Nevro (NYSE:NVRO) last released its earnings results on Thursday, May 9th. The medical equipment provider reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.79). The firm had revenue of $82.10 million during the quarter, compared to analysts’ expectations of $87.47 million. Nevro had a negative return on equity of 31.84% and a negative net margin of 19.79%. The business’s revenue was down 6.3% on a year-over-year basis. During the same period last year, the business earned ($0.59) earnings per share. On average, equities research analysts predict that Nevro Corp will post -3.83 earnings per share for the current fiscal year.
A number of analysts recently commented on NVRO shares. Zacks Investment Research upgraded shares of Nevro from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 14th. ValuEngine upgraded shares of Nevro from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Wells Fargo & Co dropped their target price on shares of Nevro from $75.00 to $70.00 and set an “outperform” rating on the stock in a report on Monday, May 13th. Canaccord Genuity downgraded shares of Nevro from a “buy” rating to a “hold” rating and dropped their target price for the stock from $62.00 to $50.00 in a report on Friday, May 10th. Finally, JMP Securities dropped their target price on shares of Nevro from $80.00 to $70.00 and set a “market outperform” rating on the stock in a report on Friday, May 10th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $57.83.
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
See Also: Recession
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.